Mobilizing resources to build a recently made known organization is an undertaking laden with uncertainty and unforeseeable hazards (Stinchcombe.

Mobilizing resources to build a recently made known organization is an undertaking laden with uncertainty and unforeseeable hazards (Stinchcombe, 1965; Aldrich and Auster, 1986; Freeman, 1997) It is also inherently a social proces because entrepreneur must access financial and social capital and other shadows of resources via business relationships with parties outside of the boundaries of their organizations Because the quality of a fresh venture is always a matter of any debate, however, the decision of external resource owners to invest their time, capital, or other resources in a recent organization is one that must be made subject to considerable uncertainty about the embryonic enterprise's life chances and its financial promises This paper investigates how interorganizational relationships, according to shaping potential investors' assessments of the quality of young companies, affect those firms' ability to obtain the resources to survive.

Interorganizational exchange relationships can act as endorsements that influence perceptions of the quality of young organizations when unambiguous measures of quality do not exist or cannot be observ As a deduction the valuations of young firms are at times attributions influenced by the agency of the characteristics of the affiliates of the companies subject to scrutiny. Because strong relationships with prominent organizations demise the fact that young companies have earned a positive evaluation from experienced and influential actors, associations with high-status organizations elevate the reputations of fresh ventures. This paper documents to what degree the performance of young biotechnology firms is affected by means of such an interorganizational certification, or endorsement proces as it operates in the industry's strategic alliance and equity ownership networks, as well as in consequence of the connections between new chances and the investment banks that underwrite their securities offerings. Our empirical analyses focus upon the degree to which the prominence of the business partners of young biotechnology companies affect their ability to acquire a crucial resource: capital.

INTERORGANIZATIONAL ENDORSEMENTS

Many obstacles oppose young companies. New organizations repeatedly lack the commitment of their employee knowledge of their environments, and working relationships with customers and suppliers (Stinchcombe, 1965) Similarly, unseasoned enterprises have little production experience, and in the same manner operate under the guidance of immature and unrefined routines (Sorensen and Stuart, 1999) Because young companies frequently are unable to produce output of consistent quality, they face a high probability of dissolution (Hannan and Freeman, 1984) Moreover, strange organizations tend to be small organizations. In part because they do not have the financial and other resources to withstand a sustained period of poor performance, the rate of disbandment among small organizations is quite high (Aldrich and Auster, 1986; Levinthal, 1991) These perils have l organizational sociologists to argue that young (or small) organizations are highly vulnerable to environmental selection, a notion succinctly portrayed as a liability of newnes (or smallness).

Because young and small companies collision so many potential hazards and because they have short track records by the agency of which outsiders can evaluate their quality, there is considerable uncertainty about the value of just discovered ventures. This uncertainty is adjusted for certain types of organizations, in the same state [i]or[/i] condition as those established to hunt commercial applications of new technologies (Aldrich and Fiol, 1993) Added to the usual hazards of inexperience, young technology companies ofttimes require substantial resources to store early-stage and speculative development plans while revenues cannot be calculate uponed until well into the futurity Moreover, new technology is on its very nature highly uncertain: undevelop markets tread in the steps of unforeseen turns; hyped-up technologies disappear far more oftentimes than they engender promised technological shifts; technologies obsolesce extremely rapidly; and unanticipated kinks derail once-promising disentanglement projects (Tushman and Rosenkopf, 1992) For these reasons, fresh technology companies are extremely risky.

The case of Microcide Pharmaceutical illustrates the challenges in evaluating young companies. builded in 1992 to develop novel antibiotics, Microcide is a genomics company. When the company filed for an initial public offering (IPO) in 1996 it had made progres in the growth of a gene function-based technology platform to identify and commercialize just discovered antibiotics. This technology enables the identification of the gene in a microorganism that cause pathogenicity in the material substance The company had already filed for 30 patents, although all of them were still being reviewed by way of the Patent Office in 1996 onward the heels of these potentially significant achievements, Microcide sought to raise $40 million for a 24-percent stake in the company in an IPO (Microcide Pharmaceuticals, SEC form S-1 1996) At the time of the offering, however, Microcide had at the same time to commercialize a product, and it garnered no returns other than milestone payments from its strategic alliance partners. In addition, the antibiotics market was hotly contested; many of the largest put drugs into companies and a significant number of upstart biotech firms were competing in this domain. Because of the intense competition in this area and the scientific uncertainty associated with Microcide's research approach, it was difficult to predict whether any of Microcide's discoveries would lead to the disentanglement of a clinically viable therapeutic. In fact, the no other than certainty at the time of the Microcide IPO was that the company was many years away from generating a significant income stream from sales of internally discloseed products.